Capillary Leak Index Versus Conventional Biomarkers in Predicting Sepsis-Related Outcomes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Capillary Leak Index Versus.
- Who it may be relevant to
- Registry conditions: Peritonitis Infectious. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to evaluate the prognostic significance of CLI in predicting 28-day mortality and other outcomes in critically ill patients who develop post-operative abdominal sepsis.
Interventions
- Diagnostic test Capillary Leak Index Versus
Blood samples will be collected at three time points: within 1-2 hours of ICU admission (Day 0), Day 1, Day 2 and Day 7, to monitor trends in CLI and conventional biomarkers during the ICU stay. • CR
Primary outcome measures
- all-cause mortality [Time frame: From 1-10-2025 to 1-10-2026]
Eligibility criteria
Inclusion criteria
Age ≥ 18 years.
Postoperative secondary peritonitis requiring ICU admission, with clinical evidence of:
Diffuse or localized abdominal pain/tenderness. Peritoneal signs (e.g., guarding, rigidity, rebound tenderness). Imaging or intraoperative confirmation of purulent/exudative intra-abdominal fluid.
Systemic inflammation (e.g., fever, leukocytosis, or vasopressor requirement). Sepsis diagnosis per Sepsis-3 criteria: Suspected/confirmed infection with acute increase in SOFA score ≥2 points (6).
Anticipated ICU stay ≥48 hours postoperatively.
Exclusion criteria
- Pregnancy
- Advanced liver disease (Child-Pugh class B or C) that might independently affect albumin levels
- Advanced kidney disease (CKD stage 4 or 5) or patients on chronic dialysis
- Expected mortality within 48 hours of ICU admission
- Patients with primary peritonitis or tertiary peritonitis
- Immunocompromised patients (e.g., on chronic immunosuppressive therapy, solid organ transplant recipients, patients with HIV and CD4 count <200/mm³)
- Patients with pre-existing systemic inflammatory diseases that might affect baseline CRP levels
- Patients participating in interventional trials that might affect outcomes
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- Benha University Hospital — Banhā
Identifiers
NCT: NCT07232342 · BenhaU123456789